Rare diseases
Investigational molecules
Locations
Study of Selinexor, Dexamethasone, and Bortezomib for Patients with Refractory Multiple Myeloma
GreeceStudy on the Effectiveness and Safety of Selinexor for Patients with Myelofibrosis and Moderate Thrombocytopenia Who Have Not Used JAK Inhibitors
BelgiumStudy of Selinexor and Gemcitabine for Patients with Advanced Soft-Tissue Sarcoma
SpainStudy of Selinexor and Gemcitabine for Patients with Advanced Soft-Tissue Sarcoma
SpainComparison of allogeneic stem cell transplantation versus conventional therapy in patients with multiple myeloma who relapsed after first-line therapy
GermanyStudy of Rituximab, Gemcitabine, Dexamethasone, and Platinum with or without Selinexor for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
ItalyStudy of Selinexor, Ifosfamide, Etoposide, and Dexamethasone for Patients with Relapsed or Refractory Peripheral T-cell Lymphomas
ItalyStudy Comparing ABBV-383 with Standard Therapies for Adults with Relapsed or Refractory Multiple Myeloma
AustriaStudy on the Effectiveness and Safety of Selinexor and Ruxolitinib for Patients with Myelofibrosis Who Have Not Received Prior Treatment
BelgiumStudy Comparing Selinexor, Pomalidomide, and Dexamethasone with Elotuzumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma
FranceStudy on Selinexor as Maintenance Therapy for Patients with Advanced or Recurrent Endometrial Cancer After Chemotherapy
BelgiumStudy of Selinexor for Patients with Previously Treated Myelofibrosis
ItalyTell us about your condition – we search every trial in Europe and connect you with the right site.
